Abstract. In this paper we discuss two models involving protein binding. The first model describes a system involving a drug, a receptor and a protein, and the question is to what extent the affinity of the drug to the protein affects the drug-receptor binding and thereby the efficiency of the drug. The second model is the basic model underlying Target-Mediated Drug Disposition, which describes the pharmacokinetics of a drug in the presence of a target, often a receptor. 1. Introduction. I
Cell-surface receptors are the most common target for therapeutic drugs. The design and optimization...
Cancer therapy benefits today from the availability of new promising classes of drugs such as thera...
We consider the relationship between the target affinity of a monoclonal antibody and its in vivo po...
Cancer therapy benefits today from the availability of new promising classes of drugs such as therap...
Cancer therapy bene ts today from the availability of new promising classes of drugs such as therape...
Abstract: Targeting receptor systems by competitive inhibition is the objective of various antibody ...
An extended pharmacokinetic/pharmacodynamic (PK/PD) model is presented, in which the effect of bindi...
Optimizing drug therapies for any disease requires a solid understanding of pharmacokinetics (the dr...
Receptor mediated endocytosis (RME) plays a major role in the disposition of therapeutic protein dru...
A mathematical model is presented that simulates the steady tency of an agonist is dependent upon th...
The study of the magnitude and variation of drug response is defined as pharmacodynamics (PDs). PD m...
The motions of proteins underlie all processes in cells, ranging from substrate transport to signal ...
Normal cellular function requires that cells respond to stimuli in their environment. One of the mos...
AbstractThe study of the magnitude and variation of drug response is defined as pharmacodynamics (PD...
Targeting receptor systems by competitive inhibition is the objective of various protein drugs in d...
Cell-surface receptors are the most common target for therapeutic drugs. The design and optimization...
Cancer therapy benefits today from the availability of new promising classes of drugs such as thera...
We consider the relationship between the target affinity of a monoclonal antibody and its in vivo po...
Cancer therapy benefits today from the availability of new promising classes of drugs such as therap...
Cancer therapy bene ts today from the availability of new promising classes of drugs such as therape...
Abstract: Targeting receptor systems by competitive inhibition is the objective of various antibody ...
An extended pharmacokinetic/pharmacodynamic (PK/PD) model is presented, in which the effect of bindi...
Optimizing drug therapies for any disease requires a solid understanding of pharmacokinetics (the dr...
Receptor mediated endocytosis (RME) plays a major role in the disposition of therapeutic protein dru...
A mathematical model is presented that simulates the steady tency of an agonist is dependent upon th...
The study of the magnitude and variation of drug response is defined as pharmacodynamics (PDs). PD m...
The motions of proteins underlie all processes in cells, ranging from substrate transport to signal ...
Normal cellular function requires that cells respond to stimuli in their environment. One of the mos...
AbstractThe study of the magnitude and variation of drug response is defined as pharmacodynamics (PD...
Targeting receptor systems by competitive inhibition is the objective of various protein drugs in d...
Cell-surface receptors are the most common target for therapeutic drugs. The design and optimization...
Cancer therapy benefits today from the availability of new promising classes of drugs such as thera...
We consider the relationship between the target affinity of a monoclonal antibody and its in vivo po...